Amplyx Raises $67m For Antifungals Against Life-Threatening Pathogens
Investors were impressed by the company's broad-spectrum, IV and oral antifungal drug in a space where few treatment options exist; Phase II trials will start later this year.
You may also be interested in...
Pfizer’s Amplyx Buy Continues Infectious Disease Deal-Making Spree
Pfizer will develop the novel antifungal fosmanogepix. The big pharma has made several other recent anti-infective deals, including when it expanded its BioNTech vaccine alliance to include COVID-19.
Finance Watch: Atea Pharmaceuticals Raises $215m For COVID-19 Antiviral
Private Company Edition: Atea and Phlow receive big money for big COVID-19 problems – treatments and manufacturing capacity. Also, Cowen raises a $493m fund and antifungal developer Amplyx increases series C round to $90m, among other recent VC deals.
Amplyx Cleared To Complete Phase II Study Of New Antifungal Class
Fosmanogepix, with safety and efficacy clearances to continue Phase II, could provide an IV-to-oral option for patients with potentially lethal Candida fungal infections.